Monitoring of extracellular pyruvate, lactate, and ascorbic acid during cerebral ischemia: a microdialysis study in awake gerbils

In vivo microdialysis coupled with liquid chromatography was developed for the continuous monitoring of brain neurochemicals during cerebral ischemia in awake, free moving gerbils. The dead volume of the microdialysis system was estimated to be less than 30 microl. The detection limits of the present assay were 0.2 to 2.0 microM for analytes at a signal to noise ratio of five. To validate this assay, a focal cerebral ischemia was produced by occlusion of one common carotid artery for 60 min and then reperfusion for additional 3 h in awake gerbils. A microdialysis probe was inserted into the striatum of the gerbil. Dialysates were autoinjected and analyzed extracellular pyruvate, lactate, and ascorbic acid by liquid chromatography with a UV detector during cerebral ischemia. Significant changes of pyruvate and the lactate/pyruvate ratio were observed. Biphasic and dynamic changes in ascorbic acid and lactate were proposed to correlate a secondary damage. This assay can be used as a tool to study dynamic changes of brain neurochemicals in awake animals.

Determination of unbound cefmetazole in rat blood by on-line microdialysis and microbore liquid chromatography: a pharmacokinetic study

A specific and sensitive microbore liquid chromatographic method for the determination of unbound cefmetazole in rat blood was developed. A microdialysis probe was inserted into the jugular vein/right atrium of a Sprague-Dawley rat. Cefmetazole (10 mg/kg, i.v.) was then administered via the femoral vein. Dialysates were automatically injected into a liquid chromatographic system via an on-line injector. Isocratic elution of cefmetazole was achieved by LC-UV within 10 min. Intra- and inter-assay accuracy and precision of the assay were < or = 10%. The detection limit of cefmetazole was 20 ng/ml. Pharmacokinetic analysis of results indicated that unbound cefmetazole levels in rats best fit a biexponential decay model.

Determination of unbound ceftriaxone in rat blood by on-line microdialysis and microbore liquid chromatography

In vivo microdialysis was used to determine unbound ceftriaxone in rat blood. A microdialysis probe was inserted into the jugular vein/right atrium of Sprague-Dawley rats, and dose of 10 mg/kg ceftriaxone was then administered via the femoral vein. Dialysates were automatically collected and injected into a liquid chromatographic system via an on-line injector. Isocratic elution of ceftriaxone within 10 min was achieved using a microbore liquid chromatographic system. The chromatographic mobile phase consisted of methanol-100 mM monosodium phosphoric acid (15:85, v/v, pH 7.0). The wavelength of the UV detector was set at 280 nm. Intra- and inter-assay accuracy and precision of the assay were less than 15%. The detection limit of ceftriaxone was 20 ng/ml. The results suggest that unbound ceftriaxone in rat blood is best fit to a biexponential decay model.

Simultaneous measurement of cefuroxime in rat blood and brain by microdialysis and microbore liquid chromatography. Application to pharmacokinetics

To characterize the pharmacokinetics of cefuroxime in rat blood and brain, microdialysis probes were inserted into the jugular vein and brain striatum, respectively. Cefuroxime (20 mg/kg, i.v.) was administered via the femoral vein. Blood microdialysates were automatic injected onto microbore liquid chromatography via an on-line injectors. The mobile phase consisted of methanol-100 mM monosodium phosphoric acid (25:75, v/v, pH 5.0) with a flow-rate of 0.05 ml/min. Ultraviolet detector was set at a wavelength of 280 nm for cefuroxime. The present assay enhanced the detection sensitivity and enabled the determination of cefuroxime down to 5 ng/ml. The pharmacokinetic data demonstrated that the area under the concentration curve (AUC) ratio of unbound cefuroxime in rat brain and blood was about 4.2% after cefuroxime (20 mg/kg, i.v.) administration. These results provided further evidence that cefuroxime could penetrate the blood-brain barrier.

Measurement of hydroxyl radical in rat blood vessel by microbore liquid chromatography and electrochemical detection: an on-line microdialysis study

Salicylic acid (0.5 mM) is used as a trapping reagent of hydroxyl radical, and the formed 2,3- and 2,5-dihydroxybenzoic acids were collected via an on-line microdialysis device from the blood vessels. This study revealed the use of a sensitive liquid chromatographic system with electrochemical detection for the determination of 2,3- and 2,5-dihydroxybenzoic acids. Mobile phase consisted of 0.1 M monochloroacetic acid, 10 mM EDTA, 0.5 mM sodium octylsulfate, 20% acetonitrile and 5% tetrahydrofuran in 1 l (pH 3.0 adjusted with 1 M NaOH), and the flow-rate of 0.05 ml/min were found to be optimum. Isocratic separation of these adducts on a microbore column (reversed-phase C18, 150x1 mm I.D., 5 microm) was achieved within 10 min. The optimal applied potential of dihydroxybenzoic acids was set at 750 mV based on a hydrodynamic study. This method has the detection limits of 1.3 pmol/ml (or 0.2 ng/ml) for 2,3- and 2,5-dihydroxybenzoic acids in Ringer solution (at signal-to-noise ratio=3).

Inhibitors of mitochondrial respiration, iron (II), and hydroxyl radical evoke release and extracellular hydrolysis of glutathione in rat striatum and substantia nigra: potential implications to Parkinson's disease

In this investigation, microdialysis has been used to study the effects of 1-methyl-4-phenylpyridinium (MPP+), an inhibitor of mitochondrial complex I and alpha-ketoglutarate dehydrogenase and the active metabolite of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), on extracellular concentrations of glutathione (GSH) and cysteine (CySH) in the rat striatum and substantia nigra (SN). During perfusion of a neurotoxic concentration of MPP+ (2.5 mM) into the rat striatum or SN, extracellular concentrations of GSH and CySH remain at basal levels (both approximately 2 microM). However, when the perfusion is discontinued, a massive but transient release of GSH occurs, peaking at 5,000% of basal levels in the striatum and 2,000% of basal levels in the SN. The release of GSH is followed by a slightly delayed and smaller elevation of extracellular concentrations of CySH that can be blocked by the gamma-glutamyl transpeptidase (gamma-GT) inhibitor acivicin. Low-molecular-weight iron and extracellular hydroxyl radical (OH*) have been implicated as participants in the mechanism underlying the dopaminergic neurotoxicity of MPTP/MPP+. During perfusion of Fe2+ (OH*) into the rat striatum and SN, extracellular levels of GSH also remain at basal levels. When perfusions of Fe2+ are discontinued, a massive transient release of GSH occurs followed by a delayed, small, but progressive elevation of extracellular CySH level that again can be blocked by acivicin. Previous investigators have noted that extracellular concentrations of the excitatory/excitotoxic amino acid glutamate increase dramatically when perfusions of neurotoxic concentrations of MPP+ are discontinued. This observation and the fact that MPTP/MPP+ causes the loss of nigrostriatal GSH without corresponding increases of glutathione disulfide (GSSG) and the results of the present investigation suggest that the release and gamma-GT/dipeptidase-mediated hydrolysis of GSH to glutamate, glycine, and CySH may be important factors involved with the degeneration of dopamine neurons. It is interesting that a very early event in the pathogenesis of Parkinson's disease is a massive loss of GSH in the SN pars compacta that is not accompanied by corresponding increases of GSSG levels. Based on the results of this and prior investigations, a new hypothesis is proposed that might contribute to an understanding of the mechanisms that underlie the degeneration of dopamine neurons evoked by MPTP/MPP+, other agents that impair neuronal energy metabolism, and Parkinson's disease.

Intrastriatal injection of 5,7-dihydroxytryptamine decreased 5-HT levels in the striatum and suppressed locomotor activity in C57BL/6 mice

Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 5,7-dihydroxytryptamine (5,7-DHT) on striatal levels of dopamine (DA), 5-hydroxytryptamine (5-HT), and their metabolites, as well as on locomotor activity were investigated in C57BL/6 mice. The results showed that MPTP significantly increased locomotor activity and decreased striatal DA levels. However, injection of the serotonergic neurotoxin 5,7-DHT in the striatum, either alone or following high doses of MPTP, significantly decreased locomotor activity, and concomitantly decreased striatal levels of 5-HT and 5-HIAA. This study suggests that the increased locomotor activity may be due to increased striatal serotonergic activity which overcompensates for the DA deficiency. The locomotor hypoactivity, induced by 5,7-DHT, might be due to the decreased striatal levels of 5-HT and 5-HIAA.

Dorsal facial area of cat medulla; 5-HT2 action on glutamate release in regulating common carotid blood flow

Serotonin (5-HT) may inhibit glutamate release in the dorsal facial area (DFA) of the medulla and decrease common carotid arterial (CCA) blood flow. We attempted to clarify which subtype(s) of 5-HT receptor was involved. A microdialysis probe was inserted in DFA. The concentration of glutamate in dialysates were determined by chromatography. Glutamate concentration was dose-dependently decreased by perfusion of 5-HT or DOI, a 5-HT2 agonist, but not by 5-CT, a 5-HT1 agonist. The 5-HT-induced decrease in glutamate was reversed by co-perfusion of ketanserin, a 5-HT2 antagonist, but not by propranolol, a 5-HT1 antagonist. CCA blood flow was decreased when 5-HT or DOI was perfused, and was reversed by co-perfusing ketanserin. In conclusion, 5-HT may inhibit glutamate release via 5-HT2 receptor in DFA, resulting in the reduction of CCA blood flow.

Pharmacokinetic and pharmacodynamic analyses of trazodone in rat striatum by in vivo microdialysis

The aim of this study was to investigate the brain pharmacokinetics and pharmacodynamics of trazodone. Sensitive microbore high-performance liquid chromatographic methods with electrochemical detection (LC-ED) were developed for the determination of trazodone, serotonin (5-HT), and their respective metabolites. The feasibility of microdialysis coupled with LC-ED system for direct analysis of these compounds in the rat striatum was investigated. Striatal dialysates were automatically injected onto a cyano microbore column, through an on-line injector, for the determination of trazodone and its metabolite or onto a reversed phase microbore column for the determination of 5-HT and its metabolite. A monophase phenomenon with a first-order elimination rate constant was observed for trazodone. The brain pharmacokinetics of trazodone appear to conform to a one-compartment model. Surprisingly, no significant changes in striatal 5-HT or its metabolite were observed following the same dosage and time course. The present results suggest that brain microdialysis methods may be applicable to pharmacokinetic and pharmacodynamic studies of psychotrophic agents.

Rapid on-line microdialysis hyphenated technique for the dynamic monitoring of extracellular pyruvate, lactic acid and ascorbic acid during cerebral ischemia

Rapid on-line microdialysis coupled with liquid chromatography was developed for the continuous monitoring of brain neurochemicals during cerebral ischemia. Isocratic separation of these analytes was achieved within 3 min, hence, over 80 analyses could be performed in a 4-h experiment. The dead volume of the microdialysis system was estimated to be less than 10 microl. The detection limits of the present assay, at a signal-to-noise ratio of five, were 2.0, 0.2 and 0.5 microM, for lactic acid, pyruvate and ascorbic acid, respectively. To validate this assay, a transient ischemia was produced by occlusion of two common carotid arteries for 10 min in an anesthetized gerbil. A microdialysis probe was inserted into the striatum of the gerbil to simultaneously monitor pyruvate, lactic acid and ascorbic acid during cerebral ischemia. Significant and dynamic changes in these analytes could be resolved in 3-min intervals. This rapid assay can be used as a tool to study dynamic changes in neurochemicals of the brain, such as during cerebral ischemia.

Involvement of catecholamines in recall of the conditioned NK cell response

The primary goal of the study was to identify the types of catecholamines and the associated receptors which might be involved in the recall of the conditioned NK cell response. Specific catecholamine receptor antagonists were selected to block the conditioned NK cell response at the recall step. The regional contents of dopamine (DA), norepinephrine (NE), and epinephrine were determined in the brain of the conditioned animals by using the high performance liquid chromatography with electrochemical detection (HPLC/ED). Results showed that pre-disruption of the central alpha1-, alpha2-, beta1-, beta2-, D1-, or D2-receptors at the conditioned recall stage, interrupted the conditioned enhancement in NK cell activity. The NE contents at the cerebellum, and DA contents at the striatum and hippocampus, were significantly higher in the brain of the conditioned animals when compared to that of the control animals. These information indicated the possible roles of the central noradrenergic and dopaminergic systems in regulating the recall of the conditioned NK cell response.

On-line microdialysis coupled with microbore liquid chromatography for the determination of unbound chloramphenicol and its glucuronide in rat blood

On-line microdialysis coupled with microbore liquid chromatography was used to investigate the pharmacokinetics of chloramphenicol and its glucuronide in rat blood. A microdialysis probe was inserted into a jugular vein of male Sprague-Dawley rats. Chloramphenicol succinate (20 mg/kg, intravenously) was then administered via a femoral vein. Dialysates were automatically injected onto a LC system, via an on-line injector. Samples were eluted with a mobile phase containing acetonitrile-10 mM monochloroacetic acid (30:70, v/v, pH 3.0). The UV detector wavelength was set at 278 nm. The limit of quantitation for chloramphenicol was 10 ng/ml. The in vitro recoveries of chloramphenicol and chloramphenicol glucuronide at 500 ng/ml were 32.2+/-0.3% and 11.4+/-0.7%, respectively (n = 6). Intra- and inter-assay accuracy and precision of the analyses were < or =10% in the range of 0.01 to 5.0 microg/ml.

Determination of naringenin and its glucuronide conjugate in rat plasma and brain tissue by high-performance liquid chromatography

An isocratic high-performance liquid chromatographic method with ultraviolet detection was utilized for the investigation of the pharmacokinetics of naringenin and its glucuronide conjugate in rat plasma and brain tissue. Plasma and brain tissue were deproteinized by acetonitrile, then centrifuged for sample clean-up. The drugs were separated by a reversed-phase C18 column with a mobile phase consisting of acetonitrile-orthophosphoric acid solution (pH 2.5-2.8) (36:64, v/v). The detection limits of naringenin in rat plasma and brain tissue were 50 ng/ml and 0.4 microg/g, respectively. The glucuronide conjugate of naringenin was evaluated by the deconjugated enzyme beta-glucuronidase. The naringenin conjugation ratios in rat plasma and brain tissue were 0.86 and 0.22, respectively, 10 min after naringenin (20 mg/kg, i.v.) administration. The mean naringenin conjugation ratio in plasma was approximately four fold that in brain tissue.

Glial cell line-derived neurotrophic factor protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity in C57BL/6 mice

To mimic chronic exposure to neurotoxins in inducing dopaminergic cell damage, multiple doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) were injected in C57BL/6 mice. Effects of pre- and post-treatment with the glial cell line-derived neurotrophic factor (GDNF) by injections into the striatum were investigated. GDNF exerts protective and reverse effects on the dopaminergic damage, supporting the potential application of GDNF in prevention and treatment of Parkinson's disease.

Elevated 5-S-cysteinyldopamine/homovanillic acid ratio and reduced homovanillic acid in cerebrospinal fluid: possible markers for and potential insights into the pathoetiology of Parkinson's disease

High-performance liquid chromatography with electrochemical detection has been employed to analyze ultrafiltrates of cerebrospinal fluid of Parkinson's Disease (PD) patients and age-matched controls for the dopamine (DA) metabolites homovanillic acid (HVA) and 5-S-cysteinyldopamine (5-S-CyS-DA). The mean level of HVA in the CSF of PD patients, measured 5 days after withdrawal from L-DOPA therapy, was significantly lower than that measured in controls. By contrast, mean levels of 5-S-CyS-DA were not significantly different in the CSF of PD patients taking L-DOPA (PD-LT patients) the same patients 5 days after discontinuing this drug (PD-LW patients) or controls. However, the mean 5-S-CyS-DA/HVA concentration ratio was significantly (p < 0.05) higher in the CSF of PD-LW patients compared to controls. Although the PD patient population employed in this study had been diagnosed with the disease several years previously and had been treated with L-DOPA for prolonged periods of time the results of this study suggest that low CSF levels of HVA and a high 5-S-CyS-DA/HVA ratio together might represent useful markers for early diagnosis of PD. The high 5-S-CyS-DA/HVA ratio observed in the CSF of PD-LW patients also provides support for the hypothesis that the translocation of glutathione or L-cysteine into neuromelanin-pigmented dopaminergic cell bodies in the substantia nigra might represent an early event in the pathogenesis of PD.

Comparative effects of heparin and the sulfatoid GM1474 on coagulation parameters in plasma and blood from various species

1. The discovery and development of novel carbohydrate molecules based on heparin biology and pharmacology requires consideration of coagulation effects in evaluating the therapeutic potential of these agents. A novel sulfatoid compound, GM1474, possessing potent antiproliferative and antiangiogenic properties similar to those of heparin, was evaluated for comparative coagulation effects. 2. In vitro and in vivo effects of GM1474 on plasma-activated partial prothromboplastin time (aPTT) and whole-blood clotting time (WBCT) were monitored in plasma and blood from various species and compared with those of heparin. GM1474 possessed approximately 21.7% of the in vitro aPTT and 4.3% of the in vitro WBCT effects relative to heparin, utilizing human plasma and blood. 3. Similar differences between GM1474 and heparin were observed in plasma and blood from mice, rats, dogs and nonhuman primates. The concentrations of GM1474 producing a two-fold increase in aPTT and WBCT in vitro in the various species ranged from 2.95 to 11.4 times the concentrations of heparin producing similar effects. 4. In in vivo evaluations in mice, the intravenous doses of GM1474 producing 50% of the maximal elevation in plasma aPTT and bleeding time (IC50s) were 2.1 and 12.0 mg/kg, respectively. These doses represented approximately 6.4- and 27.9-fold the in vivo IC50, doses of heparin causing elevations in aPTT and bleeding times, respectively. 5. The results of this study demonstrate that GM1474 possesses significantly reduced effects on coagulation relative to heparin, as determined by in vitro and in vivo testing. 6. Species differences in sensitivity to GM1474 and heparin were also observed in in vitro profiling. The order of species sensitivity to GM1474 and heparin was similar (mice>human beings>rats>non-human primates>dogs) and indicates that the mouse may be the most predictive species with respect to coagulation effects in human beings.

Monitoring of blood catecholamines by microdialysis and microbore LC with a dual amperometric detector

The accuracy of in vivo microdialysis for monitoring blood catecholamines and their metabolites in Lan-Yu mini-pigs was evaluated. To prevent blood clots and irritation, a microdialysis probe was secured in a Y-shaped tube. The tube was connected to an arterio-venous shunt, in a mini-pig, for in vivo experiments. Perfusates were injected onto a microbore LC equipped with a dual electrochemical detector (the upstream electrode was set at an oxidizing potential and the downstream electrode was set at a reducing potential. The typical large offscale peak or interfering peaks on the anodic chromatograms were mostly eliminated on the cathodic chromatograms, thereby providing reliable measurements of early eluters. Early eluates, such as norepinephrine and epinephrine, with reversible redox behaviour could be detected at the downstream reducing electrode. A comparison of the present method and a conventional blood-drawing method showed good correlation (r = 0.775-0.983 for all analytes).

Protegrin-1: a broad-spectrum, rapidly microbicidal peptide with in vivo activity

Protegrin-1 (PG-1) is a cysteine-rich, 18-residue beta-sheet peptide isolated from porcine leukocytes with antimicrobial activity against a broad range of microorganisms. The MICs of PG-1 against representative gram-positive and gram-negative bacteria ranged from 0.12 to 2 microg/ml. At these levels, PG-1 was rapidly bactericidal in vitro, reducing the number of viable CFU of either methicillin-resistant Staphylococcus aureus (MRSA) or Pseudomonas aeruginosa by more than three log units in less than 15 min. Resistance to PG-1 did not develop after 11 subculturings of P. aeruginosa or 18 subcultures of MRSA in Mueller-Hinton broth containing PG-1 at one-half the MIC. Under similar conditions of serial passage, the MICs of norfloxacin and gentamicin against P. aeruginosa increased 10 and 190 times, respectively. Similarly, the MIC of norfloxacin against MRSA increased 85 times. Immunocompetent mice inoculated intraperitoneally (i.p.) with P. aeruginosa or S. aureus exhibited 93 to 100% mortality in the vehicle control group compared with 0 to 27% mortality in animals that received a single i.p. injection of PG-1 (0.5 mg/kg of body weight). Mice inoculated with S. aureus by intravenous (i.v.) injection and dosed 0 to 60 min later with a single i.v. injection of PG-1 (5 mg/kg) had a mortality of 7 to 33%, compared to a mortality of 73 to 93% in the vehicle controls. In leukopenic mice inoculated i.v. with vancomycin-resistant Enterococcus faecium, mortality was 87% in the vehicle control group and 33% in animals that received a single i.v. injection of PG-1 (2.5 mg/kg). Taken together, these data indicate that PG-1 has potential for use as an antimicrobial agent in the treatment of local or systemic infections caused by clinically relevant pathogens.

Effect of diethylmaleate on liver extracellular glutathione levels before and after global liver ischemia in anesthetized rats

Glutathione (GSH), present in a high concentration in the liver, serves important protective functions. We investigated the effect of lowered tissue GSH content, accomplished by diethylmaleate (DEM) administration, on liver extracellular GSH levels before and after global ischemia in anesthetized rats. Liver extracellular GSH levels were determined by microdialysis perfusion and an on-line high performance liquid chromatography system. Global liver ischemia was induced by ligation of the hepatic pedicles including the hepatic artery, portal vein, and bile duct. DEM (4 mmol/kg) significantly lowered both the liver tissue GSH levels (1.36 +/- 0.26 micromol/g wet wt vs 9.50 +/- 0.55 micromol/g wet wt for the untreated) and the liver extracellular GSH levels (4.3 +/- 2.4 microM vs 25.2 +/- 8.7 microM for the untreated). Global liver ischemia induced a dramatic increase in the liver extracellular GSH level. Although the liver tissue GSH level was lowered following DEM treatment, DEM administration did not affect significantly ischemia-induced elevation of extracellular GSH (when presented as fold increase relative to basal value). In conclusion, DEM showed a direct effect on liver extracellular GSH content in anesthetized rats. However, DEM treatment did not affect the relative release of GSH following global liver ischemia.

Effect of quinapril therapy on blood pressure and serotonin change in patients with mild to moderate hypertension

BACKGROUND

Previous studies have shown that serotonin plays an important role in hypertension because of its vasoconstrictive effect, mediated through serotonergic receptors. Angiotensin-II is a potent vasopressor which facilitates the aggregation of platelets, subsequently releases serotonin. Because quinapril is an angiotensin-converting enzyme inhibitor and could result in a decrease of angiotensin-II, Quinapril was used to treat patients with mild or moderate hypertension in order to observe the change of plasma serotonin.

METHODS

Twenty-two patients, (10 males, 12 females, mean age 45 yrs) without other major medical diseases and secondary causes of hypertension, were selected for this study. High performance liquid chromatography (HPLC) with electrochemical detection was used to detect the plasma serotonin. These patients were given placebos for two weeks before the first dose of quinapril (5 mg). Thereafter, the dosage was adjusted according to the response of blood pressure to a desired value (BP < 140/90 mmHg). At about 14:00 hours on the first day, after the patient had rested for an hour and was in a quiet condition, blood was drawn by venipuncture with heparin as anti coagulant; the plasma serotonin concentration was determined for the baseline value. The plasma serotonin level was rechecked eight weeks later.

RESULTS

It was found that systolic blood pressure began to decrease significantly two weeks after quinapril therapy, and then reached a constant state. Blood pressure decreased from 174/107 mmHg to 134/87 mmHg. Among these 22 patients, there were 14 (65%) whose blood pressure reduced to a normal range. Plasma serotonin also decreased significantly from 4.69 +/- /3.67 ng/ ml to 2.89 +/-2.64 ng/ml (p < 0.05). According to this data, 15 in 22 patients (68%) had reduction of plasma serotonin. There was little correlation between change in blood pressure and change of plasma serotonin; the correlation co-efficiency is only 0.019.

CONCLUSIONS

This study shows that quinapril has an antihypertensive property and serotonin-lowering effect. Since there was no correlation between the change of serotonin and blood pressure, these two actions of quinapril might have been mediated through different mechanisms.

Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 5,7-dihydroxytryptamine on the locomotor activity and striatal amines in C57BL/6 mice

The present study examined the effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 5,7-dihydroxytryptamine (5,7-DHT) on striatal levels of dopamine (DA), 5-hydroxytryptamine (5-HT), and their metabolites homovanillic acid (HVA) and 5-hydroxyindole-3-acetic acid (5-HIAA), respectively, as well as their influence on locomotor activity in conscious C57BL/6 mice. High doses (s.c., 35-45 mg/kg per day for 10 days) of MPTP resulted in a significant (P < 0.05) increase in locomotor activity and a marked decrease of striatal DA levels. Concomitantly, the ratios of HVA to DA and 5-HIAA to 5-HT increased significantly, the latter reflecting increased 5-HIAA levels. In contrast, i.c.v. administration of the serotonergic neurotoxin 5,7-DHT, either alone or following high doses (40 mg/kg per day for 10 days) of MPTP, decreased locomotor activity. Furthermore, striatal levels of 5-HT and 5-HIAA as well as the 5-HIAA/5-HT ratio decreased significantly. Thus, the increased locomotor activity induced by chronic high doses of MPTP might be due to increased striatal 5-HT levels which appear to compensate for the loss of DA. Furthermore, the locomotor hypoactivity induced by 5,7-DHT may be secondary to the striatal 5-HT deficiency.

New dual electrochemical detector for microbore liquid chromatography. Determination of dopamine and serotonin in rat striatum dialysates

A new type of liquid chromatographic (LC) dual thin-layer amperometric detector for the simultaneous measurement of trace levels of dopamine and serotonin in microdialysates is described. The concentrations of these analytes in rat dialysates are usually in the sub-nanomolar concentration range (typically, 0.10-5.00 pg in 5-microl dialysates). With this dual electrode, a glass-lined microbore column provides excellent sensitivity, selectivity, and separation. In addition, a three- to five-fold improvement in anodic current or cathodic responses over conventional dual electrodes in microbore LC can be achieved. Due to the irreversible electrochemical properties of some interference peaks, this dual electrode provides reliable measurement of dopamine based on the cathodic signal. The detection limit (signal-to-noise ratio = 3) of this assay is 0.02 pg per injection for dopamine or serotonin. This new dual electrode allows the simultaneous measurements of basal dopamine and serotonin in rat striatum dialysates without the use of re-uptake inhibitors in perfusion medium.

The dorsal facial area of the medulla in cats: inhibitory action of serotonin on glutamate release in regulating common carotid blood flow

Whether glutamate and serotonin would release and interact in the dorsal facial area (DFA) of cat medulla to regulate common carotid arterial (CCA) blood flow was explored by placing a microdialysis probe in DFA and employing high performance liquid chromatographic technique. Glutamate concentration was dose-dependently decreased by perfusion with serotonin, or alaproclate, a serotonin reuptake inhibitor. Serotonin and glutamate concentrations were increased by perfusion with KCl, a depolarizing agent. Furthermore, CCA blood flow was decreased when glutamate concentration was reduced by serotonin or alaproclate perfusion, and conversely increased when glutamate concentration was increased by KCl perfusion. In conclusion, glutamate and serotonin releases in DFA that involve regulation of CCA blood flow are tonically mediated by nerve terminals. The glutamate release is depressed by the serotonin release.

A micro liquid chromatographic assay for the determination of plasma-unbound atenolol

An improved high performance liquid chromatographic assay for plasma-unbound atenolol is described. The assay has a wide range (10-5000 ng ml-1) of linearity and a detection limit of 5 ng ml-1 (or 0.1 ng per injection) with acceptable intra- and inter-assay reproducibilities using small volumes of plasma (100 microliters). Following administration of a single dose of atenolol to the rat, nine blood samples were collected over a period of 8 h. These samples were analyzed for atenolol concentrations by a sensitive and specific microbore high performance liquid chromatograph with a photodiode-array detector. This multi-channel detector was used to acquire spectral information on atenolol and demonstrated a superior performance in comparison to all other techniques in that both qualitative and quantitative information were acquired with the system. Because of it sensitivity and applicability to plasma analysis, the assay can be used for pharmacokinetic studies and is valuable in therapeutic drug monitoring.